Implications of Using the ND1 Gene as a Control Region for Real-Time PCR Analysis of Mitochondrial DNA Deletions in Human Skin
To the Editor:
Previous work by our group and others has demonstrated that mitochondrial DNA (mtDNA) deletions may be useful as a biomarker of cumulative ultraviolet radiation exposure in human skin (Birch-Machin, 2000) . Of particular importance is the incidence of various mtDNA deletions, including the 4977 bp ''common'' deletion, which has been strongly associated with increased sun exposure in human skin (BirchMachin et al, 1998; Ray et al, 2000) and UV irradiation in cultured skin cells (Berneburg et al, 1999) . Until recently, a rapid reliable technique has not been available for quantifying low levels (i.e., o1%) of these mitochondrial deletions . For this reason, researchers have begun to look towards real-time PCR assays to provide reliable quantification of low levels of deletions. To date, the only published real-time PCR assay for a single deletion is that for the ''common'' deletion (Koch et al, 2001) . The incidence of the common deletion, however, is likely to be only the tip of the deletion iceberg (Ray et al, 2000) , and so the spectrum of the many other mtDNA deletions has been investigated in sun-exposed skin and skin cancer (Ray et al, 2000; Durham et al, 2003) . These latter studies have been limited however due to the qualitative nature of the methodology.
Recently, a real-time Taqman PCR assay has been described, which attempts to solve this problem by claiming to quantify the level of the mtDNA deletion spectrum in muscle cells (He et al, 2002) . The assay uses two probe regions in the mitochondrial genome, firstly the control probe region in the ND1 gene, and secondly the test probe region in the ND4 gene (Fig 1) . The ND1 gene lies in the part of the genome that has been historically called the minor deletion arc, because it is thought to have very few deletions (Mitomap, 2001) . This has prompted its use as the control region in the assay. In contrast, the ND4 probe resides in the major deletion arc, an area that has been frequently reported to contain many deletions (Mitomap, 2001) . In order to estimate the level of total major arc deletions within a sample, the assay calculates the ratio of the copy number of the ND1 probe to the ND4 probe.
Using a qualitative long extension PCR technique, we have previously described a spectrum of large-scale mtDNA deletions in non-melanoma skin cancer (NMSC) samples and their histologically normal perilesional skin (Durham et al, 2003) . This study addresses the question of whether the real-time PCR deletion assay described by He et al (2002) is able to provide a robust and reliable means of quantifying the deletion spectrum that has been identified in these NMSC and perilesional skin samples.
Analysis of large-scale mtDNA deletions Large-scale mtDNA deletions were analyzed in tumor samples and the histologically normal perilesional dermis and epidermis from each NMSC patient. Within each sample, the ratio of deleted:wild-type mtDNA deletions in the major deletion arc was determined by the real-time PCR assay of He et al (2002) (Table I ). The total number of deletions was estimated by long extension PCR amplification of the whole mitochondrial genome in two regions representing the major and minor deletion arcs (Table I ). In addition, high levels (i.e., 41%) of the common deletion were quantified by a radioactive 3-primer PCR assay (Table I) . As expected, the levels of deletions estimated using the real-time PCR assay generally reflected the pattern of deletions observed with the long extension PCR and the 3-primer PCR assays. Importantly, however, in a number of samples (i.e., five of 30, highlighted as shaded columns in Table I ), the levels of deletions determined by real-time PCR were clearly lower than might be expected from the long extension PCR assay and the 3-primer PCR common deletion results. A detailed analysis of the results from these five samples showed that all harbored a specific deletion of approximately 4 kb in size as determined by the long extension PCR assay of the minor deletion arc (Table I , denoted by þ ). For example, in Patient 3, the level of total major arc deletions as determined by real-time PCR in the dermis was almost identical to the level found in the tumor from the same patient (10.7 vs 10.1, respectively), despite the dermis having a far greater number of deletions in the long extension PCR assay of the major deletion arc (i.e., 9 vs 1) and 6.8% common deletion compared to undetectable in the tumor (3-primer PCR) ( Table I) .
Identification of the 3895 bp deletion identified by the long extension PCR assay As these five patient samples all harbored an unidentified minor arc deletion of approximately 4 kb in size, a literature search on previously reported mtDNA deletions was performed. This search revealed a candidate deletion of 3895 bp in size, which had only been previously reported in diseased muscle (Moraes et al, 1992) . To confirm the presence of this candidate deletion in our patient samples, PCR primers were designed that flanked the deletion break points. These formed the basis of a sensitive 3895 bp deletion-specific PCR assay, which was then performed on our NMSC and corresponding perilesional skin samples. The results showed that all the samples that had previously exhibited the 4 kb minor arc deletion band identified by long extension PCR also produced a strong PCR product of the expected size. Automated sequencing of the cloned PCR product confirmed the identity of the deletion to be the 3895 bp deletion previously reported only in muscle (Moraes et al, 1992) .
The breakpoints of the 3895 bp deletion are at nucleotide positions 548 and 4442 (Fig 1) . The deletion region encompasses, part of the non-coding D-loop, the entire 12S rRNA, 16S rRNA and ND1 genes and part of the ND2 gene (Fig 1) . Of critical importance is that the deletion removes the ND1 region used for the control probe in the real-time PCR assay for quantification of mitochondrial deletions in the major deletion arc. The effect on the real-time PCR assay is to lower the control region copy number as detected by the assay. This will in turn alter the ratio between the ND1 control probe and the ND4 test probe data thereby lowering the perceived level of deletions in the major arc. This explains the apparent anomalies in the results from the five samples detailed in Table I (shaded columns) . More importantly, it highlights the danger of using this ND1 region in the quantification of total mitochondrial DNA deletions by this particular real-time PCR assay in human skin.
Incidence of the 3895 bp deletion in human NMSC and blood As the 3895 bp deletion PCR assay is more sensitive and specific than the long extension PCR assay of the minor arc, it was used to detect low levels of the deletion in NMSC and the corresponding perilesional skin. The results showed that the deletion was observed in 73% of samples (n ¼ 30).
The pattern of expression of the deletion appeared to depend on the type of tumor, with the deletion being found in three of the five basal cell carcinoma (BCC) tumors, whereas in the squamous cell carcinoma (SCC) patients, the deletion was observed in the perilesional dermis rather than the tumor itself. Figure 2 shows a typical example of the 3895 bp deletion PCR results for BCC, SCC, and their corresponding perilesional dermis and epidermis. In confirmation of our earlier results, those samples which had the strongest PCR products were the shaded samples in Table I where the level of deletion determined by the real-time PCR assay were much lower than one would have expected based on the long extension PCR and 3-primer common deletion data.
In mitochondrial diseases involving mtDNA deletions, the incidence of the deletion is normally absent or barely detectable in the corresponding blood of the patient (Berneburg et al, 1997) . In accordance with this situation, we did not find the 3895 bp mtDNA deletion in 12 blood samples that were investigated (the results from two samples are shown in Fig 2) .
In summary, we have shown the presence of a rarely reported minor arc 3895 bp mtDNA deletion in 73% of tumor and corresponding histologically normal perilesional skin samples (n ¼ 30). As these samples are taken from constant sun-exposed body sites (i.e., face), it is currently unknown whether the incidence of the 3895 bp deletion is associated with the degree of sun-exposure. Importantly, this deletion removes the ND1 region of the mitochondrial genome. We have provided clear evidence to show that this severely limits the usefulness of those real-time assays, which use the ND1 region for the control probe in the quantification of the mtDNA deletion spectrum particularly in human skin. Tumor and matched perilesional dermis and epidermis (denoted as T, D, and E, respectively, in the table) samples were taken from 10 NMSC patients and DNA was prepared as described previously (Durham et al, 2003) . Using long extension PCR, the deletion spectrum of large-scale deletions in the mitochondrial genome was investigated by amplification of 5.5 and 11.1 kb regions representing the minor and major arcs of the mitochondrial genome respectively (Ray et al, 2000) . The number of deletions in the major arc was estimated by counting the number of PCR bands observed in the long extension PCR assay (top, i.e., first row, of results). In order to quantify the level of the 4977 bp common mtDNA deletion, a competitive, radioactive, 3-primer PCR assay was used (row 2 of results). This assay quantifies the ratios of both deleted and wild-type mtDNA and expressed as a percentage (Sciacco et al, 1994; Birch-Machin, 1998) . nd, deletion not detected. Real-time PCR of the major arc deletions was carried out as described previously (He et al, 2002) (row 3 of results). Briefly, PCR primers and fluorogenic probes for regions ND1 (forward primer, L3485-L3504; reverse primer, H3532-3553; probe, L3506-3529) and ND4 (forward primer, L12087-12109); reverse primer, H12140-12170; probe L12111-12138) were used, with ND1 acting as the control probe region. Fifty ng of sample DNA was amplified separately with the ND1 and ND4 primer/probe combinations. The total percentage of major arc deletions was quantified by calculation of the ratio of ND1 to ND4 probe amplification using the CT values. Bottom row (i.e., row 4) of results; þ symbol defines those samples that harbored the 3895 bp (originally identified as 4 kb) deletion as determined by long extension PCR of the minor arc.
Figure 2
Incidence of the 3895 bp deletion in NMSC and blood. The 3895 bp deletion PCR was carried out in a 25 mL reaction containing 200 ng genomic DNA, 600 nM of each primer, 250 mM dNTPs, 0.6 U per reaction Amplitaq Gold DNA polymerase (Applied Biosystems), GeneAmp buffer (containing, 100 mM Tris-HCl, pH 8.3, 500 mM KCl, 15 mM MgCl and 0.01% (wt/vol) gelatin). The PCR primers used were L404 (5 0 CTT TTG GCG GTA TGC ACT TT 3 0 ) (404-423nt) and H4676 (5 0 GAT TAT GGA TGC GGT TGC TT 3 0 ) (4657-4676nt). Primers L404 and H4676 were designed to anneal outside the 3895 bp deletion. During DNA amplification the polymerase extension time was designed to be too short for amplification of wild-type PCR products allowing only amplification of the shorter deleted mtDNA fragment. The PCR conditions were 941C for 10 min, 35 cycles of 941C for 30 s, 561C for 30 s, 721C for 30 s and a final extension of 7 min at 721C. This ethidium bromide stained 1% agarose gel shows a typical example of the 3895 bp deletion PCR results for the NMSCs, their corresponding perilesional dermis and epidermis and blood. Lanes 1 and 11 ¼ molecular weight markers (Hyperladder IV, range 1000-100 bp, Bioline Ltd, London, UK); lanes 2-4 ¼ tumor, dermis, and epidermis of a BCC patient; lanes 5-7 ¼ tumor, dermis, epidermis of a SCC patient; lanes 8 and 9 ¼ blood; lane 10 ¼ no DNA control.
